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OARSI TREATMENT GUIDELINES FOR HIP AND KNEE
OSTEOARTHRITIS
George Nuki, Roland Moskowitz, Weiya Zhang
Purpose: To develop evidence-based international consensus
recommendations for the management of hip and knee os-
teoarthritis (OA).
Methods: Sixteen experts drawn from rheumatology, primary
care, orthopaedics and evidence-based medicine and from 6
countries formed the guidelines development team. A systematic
review of the quality and contents of existing guidelines for
the management of hip and knee OA published between 1945
and January 2006 was initially undertaken using the validated
AGREE instrument. The management modalities and levels of
evidence for treatment recommendations in these guidelines
were analysed. Evidence relating to each modality of therapy
was based on a systematic review conducted for EULAR in
2002 that was updated from January 2002 – January 2006 using
MEDLINE, EMBASE, CINAHL, AMED, the Cochrane Library
and HTA reports. The quality of evidence was evaluated, and
where possible, outcome data for efficacy, adverse effects and
cost-effectiveness were abstracted. The effect size (ES), number
needed to treat (NNT), relative risk (RR) or odds ratio (OR)
and cost per quality of life years (QALY) gained were estimated.
Consensus recommendations were produced following a Delphi
exercise and the strength of recommendation for propositions
relating to each modality was determined using a visual analogue
scale (VAS).
Results: Twenty-three out of 1462 guidelines or consensus
statements retrieved from the literature search met the inclu-
sion/exclusion criteria. Six were predominantly based on expert
opinion, 5 were primarily based on research evidence and 12
were based on both. AGREE scores for the quality of the guide-
lines were highest in hybrid guidelines (51%) and higher in
those that were exclusively evidence-based (41%) than in those
that were solely based on expert consensus (28%) (p< 0.05).
However, the overall quality was poor (42%). Thirty-five out of
50 treatment modalities addressed were supported by evidence
from randomised controlled trials (RCTs) or systematic reviews
of RCTs, but only 19 of these were universally recommended.
Evidence for the efficacy of some, but not all these modalities
of therapy was strengthened by the results of trials since 2002.
Examples of modalities of treatment supported by the results
of more recent RCTs include exercise (strengthening ES 0.32,
95%CI 0.23, 0.42; aerobic ES 0.52, 95%CI 0.34, 0.70; and
water-based ES 0.25, 95%CI 0.02, 0.47) and NSAIDs (ES 0.32,
95%CI 0.24, 0.39). Examples of treatment modalities where re-
cent trials have failed to confirm efficacy include ultrasound (ES
0.06, 95%CI -0.39, 0.52), massage (0.10 95%CI -0.23, 0.43)
and heat/ice therapy (ES 0.69, 95%CI -0.07, 1.45). The updated
evidence on adverse effects associated with pharmacological
treatments also varied from treatment to treatment. For example,
while the gastrointestinal (GI) toxicity of non-selective NSAIDs
and the increased risk of myocardial infarction associated with
rofecoxib were reinforced; other potential adverse effects such
as GI toxicity with acetaminophen and myocardial infarction due
to celecoxib remain inconclusive.
Draft recommendations in the form of propositions were based
on the critical appraisal of the existing guidelines, the system-
atic update of the research evidence for benefit and harms
and the clinical expertise of the OARSI guidelines development
group. The draft consensus recommendations suggest that op-
timal management of patients with OA of the hip and knee
requires a combination of non-pharmacological and pharmaco-
logical modalities of treatment in most patients and surgery in
some. Non-pharmacological modalities proposed for recommen-
dation include the provision of information access, education
about the objectives of treatment and the importance of changes
in lifestyle, exercise, weight reduction and the appropriate use
of walking aids, patellar taping, modified footwear, knee braces
and the use of acupuncture and transcutaneous electrical nerve
stimulation (TENS) in selected patients. Pharmacological treat-
ments proposed for recommendation include acetaminophen (up
to 4g/day) as the preferred oral analgesic for initial therapy.
Alternative/additional analgesics to be considered for patients
who do not respond to acetaminophen include oral NSAIDs
at the lowest effective doses, topical capsaicin or NSAIDs as
well as intra-articular injections of corticosteroids or hyaluronans.
The draft recommendations suggest that the choice should be
based on consideration of co-morbidities, concomitant medica-
tion and relative efficacy and safety. In patients with increased
GI risk, a COX-2 selective agent or a non-selective NSAID
with co-prescription of a proton pump inhibitor or misoprostol
for gastroprotection may be considered, but NSAIDs, including
COX-2 selective agents, should be used with caution in patients
with risk factors for cardiovascular disease. Glucosamine and/or
chondroitin sulphate may provide some symptomatic benefit in
patients with knee OA. It is suggested that the use of opioid
analgesics should only be considered in exceptional circum-
stances for the treatment of severe and refractory pain where
other agents have been ineffective or are contraindicated.
It is proposed that patients with hip or knee OA who are not ob-
taining adequate pain relief and functional improvement from a
combination of pharmacological and non-pharmacological treat-
ment should be considered for joint replacement surgery. Evi-
dence is available to show that replacement arthroplasties are
cost-effective interventions for patients with significant symptoms
and/or functional limitation associated with a reduced health-
related quality of life despite conservative therapy. Unicompart-
mental knee replacements are effective in patients with knee
OA where only one compartment is affected, and high tibial os-
teotomy can delay the need for joint replacement for up to 10
years in such patients. Osteotomy and joint- preserving surgi-
cal procedures should also be considered in young adults with
symptomatic hip OA, especially when this is associated with hip
dysplasia or coxa varus/valgus deformity. Joint fusion can be
considered as a salvage procedure when joint replacement has
failed.
The strength of recommendation for each proposition and modal-
ity of therapy has still to be determined, as has their relative
value for patients with hip or knee OA and their relative utility
for different care providers. The draft OARSI consensus recom-
mendations will be posted on the OARSI website and presented
at the OARSI congress for discussion and input from OARSI
members. They will then be finalized by the development group
and published in Osteoarthritis and Cartilage following approval
by the OARSI Board of directors.
Conclusion: A core set of pharmacological, non-pharmacolog-
ical and surgical treatments for hip and/or knee osteoarthritis
has been identified from existing evidence-based and consen-
sus guidelines, and from a systematic review of trials published
in the last 4 years; and their benefits and harms have been
evaluated. Draft OARSI recommendations for therapy based
on critical assessment of existing guidelines, recent research
evidence and clinical expertise have been formulated. It is an-
ticipated that when finalized following feedback from OARSI
members that these international, evidence-based consensus
recommendations, may be adapted for use by physicians and al-
lied health professionals involved in the management of patients
in both primary and secondary care settings in different countries.
They may also be useful to funding authorities and government
agencies responsible for regional or national provision of health
services
